Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistry
Cancer · 2025
DOI: 10.1002/cncr.35950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Shyam A Patel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: NIH HHS.
Abstract (Originalsprache)
Background
The prolonged turnaround time for next‐generation sequencing (NGS) results may be a barrier to the timely selection of therapeutics in myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) with mutated TP53 . Biomarker validation for early detection of TP53 mutation may have a significant impact on clinical decision‐making.
Methods
In this study, p53 immunohistochemistry (IHC) (index test) and TP53 NGS (referent test) were performed on 145 bone marrow specimens from 82 unique patients with TP53 ‐mutant MDS or AML to validate IHC as an early surrogate for NGS, and to assess the prognostic relevance of IHC. Results p53 IHC testing was able to correctly identify 95.5% of patients with TP53 ‐mutant MDS and 100% of patients with TP53 ‐mutant AML in this cohort. The mean p53 stain positivity was higher for AML compared to MDS (28% ± 3.67% vs. 8.8% ± 1.61%; p < .001), as well as for multihit TP53 compared to monoallelic TP53 . Bootstrap analysis with 2000 iterations showed that a p53 IHC of 7% was the threshold best associated with multihit TP53 . False‐negative results were obtained with IHC in all TP53 sole nonsense or frameshift mutations. IHC positivity was inversely correlated with overall survival (OS), with the highest quintile of p53 positivity showing a median OS of just 2.53 months.
Conclusions
IHC is a useful biomarker for the early detection of TP53 ‐mutant MDS or AML and for prediction of TP53 allelic state. The results suggest a role for IHC across global markets, especially in geographic areas with inaccessibility to NGS testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Center for Clinical and Translational Science, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Cancer Biology Program, Morningside Graduate School of Biomedical Sciences, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Department of Pathology, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
ORCID-Profile: Shyam A Patel, Noah Littman, Jan Cerny
Förderung
- NIH HHS
Zitieren
APA
Patel, S. A., Khedr, S., Gordon, C. D., Nuvvula, S., Littman, N., Woda, B., Hutchinson, L., Li, S., Xie, Y., Selove, W., Cerny, J., & Gerber, J. M. (2025). Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistry. Cancer. https://doi.org/10.1002/cncr.35950
Vancouver
Patel SA, Khedr S, Gordon CD, Nuvvula S, Littman N, Woda B, et al. Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistry. Cancer. 2025. doi:10.1002/cncr.35950
BibTeX
@article{Patel2025,
author = {Patel, Shyam A and Khedr, Salwa and Gordon, Caroline D and Nuvvula, Sri and Littman, Noah and Woda, Bruce and Hutchinson, Lloyd and Li, Shaoguang and Xie, Yiyu and Selove, William and Cerny, Jan and Gerber, Jonathan M},
title = {Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistry},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35950}
}
EUVIMED